Top Markets
Coin of the day
Hubei Biocause Pharmaceutical Co., Ltd. Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627
Kedudukan dalam Saham #9082
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a... Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Harga Saham
$0.2219522
Disegerakkan terakhir: 2025-09-11
Modal Pasaran
$1.10B
Perubahan (1 hari)
0.04%
Perubahan (1 tahun)
0.17%
Negara
CN
Perdagangan Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Hasil untuk Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Hasil pada Sep 2024 TTM: $11.64B
Menurut laporan kewangan terkini daripada Hubei Biocause Pharmaceutical Co., Ltd., hasil semasa syarikat (TTM) ialah $11.64B. Pada tahun 2022, syarikat memperoleh hasil sebanyak $7.19B penurunan berbanding hasil pada tahun 2021 iaitu $7.80B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Hubei Biocause Pharmaceutical Co., Ltd. dari 2000 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $11.64B 65.85%
2023 $7.02B -2.39%
2022 $7.19B -7.80%
2021 $7.80B 16.95%
2020 $6.67B -7.46%
2019 $7.21B 60.19%
2018 $4.50B -45.18%
2017 $8.21B 235.32%
2016 $2.45B 2,837.70%
2015 $83.33M -36.00%
2014 $130.20M -18.41%
2013 $159.58M 27.62%
2012 $125.04M -30.47%
2011 $179.84M -5.88%
2010 $191.07M 35.24%
2009 $141.29M 6.03%
2008 $133.26M 16.42%
2007 $114.46M 59.34%
2006 $71.83M 11.78%
2005 $64.26M 14.85%
2004 $55.95M 9.55%
2003 $51.07M 21.26%
2002 $42.12M -2.10%
2001 $43.02M 10.51%
2000 $38.93M 0.00%
Hasil untuk syarikat atau pesaing serupa